The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 8, Pages 2907
Publisher
MDPI AG
Online
2020-04-22
DOI
10.3390/ijms21082907
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pan-cancer analysis of whole genomes
- (2020) NATURE
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
- (2020) Ufuk Degirmenci et al. Cells
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Targeting the Bcl-2 Family in B Cell Lymphoma
- (2019) Clare M. Adams et al. Frontiers in Oncology
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
- (2019) Miguel A. Sanz et al. BLOOD
- High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype
- (2019) Håkon Reikvam et al. Journal of Clinical Medicine
- How I treat acute myeloid leukemia in the era of new drugs
- (2019) Courtney D. DiNardo et al. BLOOD
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM
- (2019) Watanabe et al. Cancers
- Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy
- (2019) Ida Sofie Grønningsæter et al. Cells
- Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
- (2018) Lauren Herschbein et al. BLOOD REVIEWS
- Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia
- (2018) Sushma Bartaula-Brevik et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison
- (2018) Ina Nepstad et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism
- (2018) Ina Nepstad et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
- (2018) Feifei Liu et al. Acta Pharmaceutica Sinica B
- Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells
- (2018) Olga Pereira et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
- (2018) Ina Nepstad et al. Cancers
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
- (2018) Abhishek Maiti et al. Clinical Lymphoma Myeloma & Leukemia
- Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience
- (2018) Carla Filì et al. LEUKEMIA RESEARCH
- Syk inhibitors in clinical development for hematological malignancies
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells
- (2017) L Poulain et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
- (2017) G L Uy et al. Blood Cancer Journal
- Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism
- (2017) Thomas Farge et al. Cancer Discovery
- The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma
- (2017) Rachel Piddock et al. Cancers
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses
- (2016) Velizar Shivarov et al. HAEMATOLOGICA
- Isocitrate dehydrogenase mutations in myeloid malignancies
- (2016) B C Medeiros et al. LEUKEMIA
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- BEZ235: When Promising Science Meets Clinical Reality
- (2016) G. Pongas et al. ONCOLOGIST
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
- (2016) I De Kouchkovsky et al. Blood Cancer Journal
- MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses
- (2016) Velizar Shivarov et al. HAEMATOLOGICA
- Central role of PI3K-SYK interaction in fibrinogen-induced lamellipodia and filopodia formation in platelets
- (2016) Raghvendra Singh FEBS Open Bio
- Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer
- (2015) Mariya O. Krisenko et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells
- (2015) Andreas Reinisch et al. SEMINARS IN HEMATOLOGY
- Mass spectrometry in leukemia research and treatment
- (2015) John Roboz et al. Expert Review of Hematology
- Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth
- (2015) Lijun Qin et al. Oncotarget
- Rational Combinations of Targeted Agents in AML
- (2015) Prithviraj Bose et al. Journal of Clinical Medicine
- Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
- (2015) Håkon Reikvam et al. Oncotarget
- Extramedullary disease in APL: A real phenomenon to contend with or not?
- (2014) Chezi Ganzel et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value
- (2014) W.-L. Chen et al. BLOOD
- SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
- (2014) Alexandre Puissant et al. CANCER CELL
- Clinical development of demethylating agents in hematology
- (2014) Shyamala C. Navada et al. JOURNAL OF CLINICAL INVESTIGATION
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- 3Omics: a web-based systems biology tool for analysis, integration and visualization of human transcriptomic, proteomic and metabolomic data
- (2013) Tien-Chueh Kuo et al. BMC Systems Biology
- Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect
- (2013) Håkon Reikvam et al. BRITISH JOURNAL OF HAEMATOLOGY
- Predicting effects of kinase inhibitor in therapy for myeloid malignancies – the challenges in capturing disease heterogeneity
- (2013) Håkon Reikvam et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
- (2013) Ivana Gojo et al. INVESTIGATIONAL NEW DRUGS
- SYK regulates mTOR signaling in AML
- (2013) J Carnevale et al. LEUKEMIA
- A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse
- (2013) S Park et al. LEUKEMIA
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
- (2013) Deepa Sampath et al. LEUKEMIA RESEARCH
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- (2013) Francesco Lo-Coco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
- (2013) J.-H. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
- (2013) Francesco Lococo et al. Mediterranean Journal of Hematology and Infectious Diseases
- Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia
- (2012) S Anguille et al. LEUKEMIA
- Signaling in Control of Cell Growth and Metabolism
- (2012) P. S. Ward et al. Cold Spring Harbor Perspectives in Biology
- Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)
- (2011) Sergio Amadori et al. BRITISH JOURNAL OF HAEMATOLOGY
- Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
- (2011) Nicolas Goardon et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
- (2011) Anna Szmigielska-Kaplon et al. CURRENT CANCER DRUG TARGETS
- Syk Regulates Multiple Signaling Pathways Leading to CX3CL1 Chemotaxis in Macrophages
- (2011) Haein Park et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status
- (2011) G Tsykunova et al. LEUKEMIA
- Stem cell gene expression programs influence clinical outcome in human leukemia
- (2011) Kolja Eppert et al. NATURE MEDICINE
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction
- (2010) D. C. Taussig et al. BLOOD
- ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
- (2010) Audrey Carriere et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome
- (2010) Patries M. Herst et al. JOURNAL OF LEUKOCYTE BIOLOGY
- mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells
- (2010) Weina Chen et al. Molecular Cancer
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
- (2010) Katrin Düvel et al. MOLECULAR CELL
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
- (2009) A. E. Perl et al. CLINICAL CANCER RESEARCH
- Optimal targeting of the mTORC1 kinase in human cancer
- (2009) Heidi A Lane et al. CURRENT OPINION IN CELL BIOLOGY
- Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML
- (2009) Alexandra Boehm et al. European Journal of Internal Medicine
- Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody
- (2009) N. Chapuis et al. HAEMATOLOGICA
- Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
- (2009) S. Park et al. HAEMATOLOGICA
- The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia
- (2009) N Gallay et al. LEUKEMIA
- The nuts and bolts of AGC protein kinases
- (2009) Laura R. Pearce et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- Functional proteomic profiling of AML predicts response and survival
- (2008) S. M. Kornblau et al. BLOOD
- The Warburg Effect in Leukemia-Stroma Cocultures Is Mediated by Mitochondrial Uncoupling Associated with Uncoupling Protein 2 Activation
- (2008) I. Samudio et al. CANCER RESEARCH
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
- (2008) D. A. Rizzieri et al. CLINICAL CANCER RESEARCH
- S6K Directly Phosphorylates IRS-1 on Ser-270 to Promote Insulin Resistance in Response to TNF-α Signaling through IKK2
- (2008) Jin Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started